ceftaroline fosamil (Zinforo)

in the absence of a submission from the holder of the marketing authorisation

ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Scotland.

Indication under review: treatment of 

• complicated skin and soft tissue infections in children from the age of 2 months 
• community-acquired pneumonia in children from the age of 2 months

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland. 

SMC has previously issued accepted ceftaroline fosamil for restricted use in adults with known of suspected meticillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infection and this advice remains in place. 

______________________________________________________________________________________

From January 2020, ADTCs may make formulary decisions on paediatric licence extensions for medicines previously accepted for use (or restricted use) for the corresponding indication in adults, taking account of relevant restrictions. This approach may also be applied retrospectively to medicines accepted for use in adults but not recommended in the corresponding indication in children due to absence of submission. PASAG liaises with companies to extend any PAS to include the younger age group and confirms arrangements with Boards.